Q2 2026 13F · SEC CIK 2032331

Arrowpoint Investment Partners (Singapore) Pte. Ltd.

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $339.9M
Reported positions: 124
Holdings vs S&P 500, 3 yrs: —
Average holding period: 1 qtrs

Arrowpoint Investment Partners (Singapore) Pte. Ltd. is a hedge fund that reported 124 positions worth $339.9M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Citigroup Inc (C, 9.7%), Goldman Sachs Group Inc (GS, 9.2%), Global Pmts Inc (GPN, 8.2%).

Arrowpoint Investment Partners (Singapore) Pte. Ltd. holdings largest 50 of 124 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Arrowpoint Investment Partners (Singapore) Pte. Ltd. 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
CCitigroup Inc	9.7%	—	235,033	—	$32.9M
GSGoldman Sachs Group Inc	9.2%	—	30,971	—	$31.3M
GPNGlobal Pmts Inc	8.2%	—	384,114	—	$27.9M
NSCNorfolk Southn Corporation	7.5%	—	81,332	—	$25.6M
AEPAmerican Elec Pwr Co Inc	7.5%	—	185,962	—	$25.4M
NVDANvidia Corporation	7.4%	—	125,539	—	$25.1M
XOMExxon Mobil Corp	7.2%	—	179,273	—	$24.5M
GOOGLAlphabet Inc	3.6%	13.3%	34,557	+11.0%	$12.3M
MUMicron Technology Inc	2.2%	—	6,519	—	$7.5M
INTCIntel Corp	1.4%	—	33,371	—	$4.7M
SNDKSandisk Corp	1.3%	—	2,008	—	$4.6M
ARGNFArgenx SE	1.2%	—	4,392	—	$4.1M
INFYInfosys Ltd	1.1%	—	367,077	—	$3.9M
CATCaterpillar Inc	1.1%	—	3,539	—	$3.8M
AXSMAxsome Therapeutics, Inc.	1.0%	4.1%	13,831	-15.7%	$3.4M
INSMInsmed Inc	0.9%	1.7%	30,170	+329.9%	$3.2M
UNHUnitedhealth Group Inc	0.9%	2.1%	7,657	+46.8%	$3.2M
BRKRBruker Corp	0.9%	—	52,780	—	$3.2M
MDGLMadrigal Pharmaceuticals Inc	0.9%	0.9%	5,865	+392.0%	$3.1M
TVTXTravere Therapeutics Inc	0.9%	—	55,112	—	$3.1M
HUMHumana Inc	0.9%	—	7,839	—	$3.1M
LLYEli Lilly & Co	0.9%	0.6%	2,548	+476.5%	$3.1M
RVTYRevvity Inc	0.9%	—	27,316	—	$3.0M
PTCTPtc Therapeutics Inc	0.9%	4.0%	36,873	-7.1%	$3.0M
ABBVAbbvie Inc	0.9%	—	11,928	—	$3.0M
CHEChemed Corp New	0.9%	—	6,365	—	$3.0M
SOXXIshares Tr	0.9%	—	4,590	—	$2.9M
AAgilent Technologies Inc	0.9%	—	21,826	—	$2.9M
NBIXNeurocrine Biosciences Inc	0.8%	4.2%	16,490	-23.5%	$2.8M
TEVATeva Pharmaceutical Inds Ltd	0.8%	1.2%	81,993	+217.7%	$2.8M
ALABAstera Labs Inc	0.8%	—	5,293	—	$2.6M
COOCooper Cos Inc	0.7%	0.6%	34,743	+489.3%	$2.5M
TWSTTwist Bioscience Corp	0.6%	1.0%	20,287	+50.5%	$2.1M
QCOMQualcomm Inc	0.6%	—	11,141	—	$2.1M
ACHCAcadia Healthcare Company in	0.6%	—	66,843	—	$2.0M
DVADavita Inc	0.5%	—	8,046	—	$1.8M
ALNYAlnylam Pharmaceuticals Inc	0.5%	—	5,588	—	$1.7M
CONConcentra Group Holdings Par	0.5%	—	52,747	—	$1.6M
BMRNBiomarin Pharmaceutical Inc	0.5%	4.1%	27,041	-44.5%	$1.5M
BIIBBiogen Inc	0.4%	1.3%	6,838	+45.3%	$1.5M
OSCROscar Health, Inc.	0.4%	—	51,105	—	$1.5M
LRCXLam Research Corp	0.4%	—	3,230	—	$1.4M
XLVSelect Sector Spdr Tr	0.4%	—	8,600	—	$1.4M
AVTRAvantor Inc	0.4%	—	131,088	—	$1.3M
RMBSRambus Inc Del	0.4%	—	9,559	—	$1.3M
EWTIshares Inc	0.4%	1.3%	11,100	-11.2%	$1.2M
RVMDRevolution Medicines Inc	0.3%	1.2%	6,100	-23.5%	$1.1M
MRNAModerna Inc	0.3%	1.3%	14,841	-13.2%	$1.0M
BBIOBridgebio Pharma Inc	0.3%	0.6%	13,454	+132.6%	$1.0M
IONSIonis Pharmaceuticals Inc	0.3%	4.4%	12,338	-68.4%	$978K

What Arrowpoint Investment Partners (Singapore) Pte. Ltd. bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Added to

COO Cooper Cos Inc+489.3% shares
LLY Eli Lilly & Co+476.5% shares
MDGL Madrigal Pharmaceuticals Inc+392.0% shares
INSM Insmed Inc+329.9% shares
TEVA Teva Pharmaceutical Inds Ltd+217.7% shares
BBIO Bridgebio Pharma Inc+132.6% shares
TWST Twist Bioscience Corp+50.5% shares
UNH Unitedhealth Group Inc+46.8% shares

Reduced

IONS Ionis Pharmaceuticals Inc-68.4% shares
BMRN Biomarin Pharmaceutical Inc-44.5% shares
NBIX Neurocrine Biosciences Inc-23.5% shares
RVMD Revolution Medicines Inc-23.5% shares
AXSM Axsome Therapeutics, Inc.-15.7% shares
MRNA Moderna Inc-13.2% shares
EWT Ishares Inc-11.2% shares
PTCT Ptc Therapeutics Inc-7.1% shares

Left the top 50

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +12.1% /yr; S&P 500 +20.1%
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$339.9M	124
Q1 2026	$67.3M	76
Q4 2025	$678.7M	104
Q3 2025	$67.2M	67
Q2 2025	$56.6M	34
Q1 2025	$214.6M	298
Q4 2024	$164.2M	226

Questions about Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s portfolio

What stocks does Arrowpoint Investment Partners (Singapore) Pte. Ltd. own?

Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 124 positions worth $339.9M. The largest are Citigroup Inc (C) at 9.7%, Goldman Sachs Group Inc (GS) at 9.2%, Global Pmts Inc (GPN) at 8.2%, Norfolk Southn Corporation (NSC) at 7.5% and American Elec Pwr Co Inc (AEP) at 7.5%.

What did Arrowpoint Investment Partners (Singapore) Pte. Ltd. buy last quarter?

In Q2 2026, Arrowpoint Investment Partners (Singapore) Pte. Ltd. added Cooper Cos Inc (COO) (+489.3% shares), Eli Lilly & Co (LLY) (+476.5% shares) and Madrigal Pharmaceuticals Inc (MDGL) (+392.0% shares), compared with its Q1 2026 filing.

What did Arrowpoint Investment Partners (Singapore) Pte. Ltd. sell last quarter?

In Q2 2026, Arrowpoint Investment Partners (Singapore) Pte. Ltd. cut from its top 50 Ase Technology Hldg Co Ltd (ASX), cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Pfizer Inc (PFE), cut from its top 50 Regeneron Pharmaceuticals (REGN), cut from its top 50 Johnson & Johnson (JNJ), Ionis Pharmaceuticals Inc (IONS) (-68.4% shares), Biomarin Pharmaceutical Inc (BMRN) (-44.5% shares) and Neurocrine Biosciences Inc (NBIX) (-23.5% shares), compared with its Q1 2026 filing.

When is Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s next 13F filing due?

13F filings are due 45 days after each quarter ends. Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.